The efficacy and safety of Fexuprazan-based triple therapy compared with a PPI-based triple therapy for Helicobacter pylori eradication

Kangwon National University Hospital0 个研究点目标入组 80 人开始时间: 待定最近更新: 2023年6月26日

适应症

试验速览

暂无简介。

•Patients with atrophic gastritis, peptic ulcer disease, low grade MALT lymphoma, functional dyspepsia, idiopathic thrombotic purpura, gastric cancer or gastric adenoma diagnosed after endoscopic resection, family history of gastric cancer who tested positive for Helicobacter pylori using rapid urease test and urea breath test

•1) Helicobacter pylori eradication in the past
•2) Patients who must take PPI, antibiotcs or steroids for other purposes
•3) Patients taking antiviral agents for AIDS
•4) Patients taking P-CAB, PPI, H2 antagonist within 2 weeks prior to screening
•5) Patients with acid secretion disorders, Zollinger–Ellison, and who have taken total or subtotal gastrectomy
•6) patients with kidney and liver failure with AST, ALT, ALP, ?-GT, total bilirubin level above 2UNL, and BUN, creatinine above 1.5 UNL
•7) patients with active gastric bleeding
•8) patients with abnormal EKG such as prolonged QT
•9) Patients who are unwilling to take contraceptive measures during clinical trial
•10) Pregnancy or breastfeeding patients
•11) Patients evaluated to be unfil for enrollment
•12) patietns with centra nervous infection, hypokalemia, or hypomagnesemia

发起方